Abstract: Objective：Study was performed on the safety and efficacy of telbivudine in blocking HBV intrauterine infection of fetus in late pregnancy. Methods：In 134 cases with chronic hepatitis B is that of women in late trimester of pregnancy of 22-32 weeks when they visited our hospital, based on the wishes of patients. 134 cases were divided into treatment group（n=86, treated with oral telbivudine antiviral therapy） and control group（n=48, given with compound glycyrrhizin tablets treatment）. After the full-term babies delivered the umbilical cord blood were taken for testing of HBsAg, within 24 h for neonatal hepatitis B vaccine injection 10 μg and hepatitis B immune globulin 200 IU, at the same time sequential administration of hepatitis B vaccine immunization. Results：Patients′ age, HBV DNA quantitative, gestational weeks and liver function indexes （ALT, AST） had no significant difference before the treatments in the two groups（P＞0.05）. After treatment, HBV DNA quantitative, liver function indexes were lower than those in the control group when the pregnancies termination（P＜0.05）. The positive rate of HBsAg in treatment group was lower than that in the control group（P＜0.05） at the birth. However, the mode of delivery in patients of the 2 groups had no effect on neonatal hepatitis B infection rate（P＞0.05）. Different mode of delivery of neonatal HBV infection had no significant difference after one year（χ2CMH=0.067 8，P=0.794 5）. Conclusions：The treatment of oral telbivudine blocking HBV intrauterine infection is safe and effective, and is worthy of further promotion.

Key words: Hepatitis B, chronic, Pregn, Disease transmission, vertical, Telbivudine